Literature DB >> 25204970

MiR-338 suppresses the growth and metastasis of OSCC cells by targeting NRP1.

Chunxi Liu1, Zhiyu Wang, Yi Wang, Wuwei Gu.   

Abstract

MicroRNAs (miRNAs) are small non-coding RNAs that have been suggested to play an essential role in tumorigenesis. Reduced expression of miR-338 has been reported in several types of cancers; however, the role of miR-338 in oral squamous cell carcinoma (OSCC) has not been elucidated. In this study, we demonstrated that miR-338 was dramatically downregulated in OSCC tissues and cell lines. Overexpression of miR-338 significantly inhibited proliferation, colony formation, migration, and invasion of OSCC cells. In addition, neuropilin1 (NRP1) was identified as a target of miR-338 in OSCC cells and inversely correlated with miR-338 in OSCC tissues. Furthermore, restoration of NRP1 attenuated the tumor-suppressive effects of miR-338. Taken together, miR-338 might inhibit growth and metastasis of OSCC cells by targeting NRP1.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25204970     DOI: 10.1007/s11010-014-2211-3

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  24 in total

1.  Decreased expression of miR216a contributes to non-small-cell lung cancer progression.

Authors:  Ren-Tao Wang; Meng Xu; Cheng-Xiong Xu; Zhi-Gang Song; Hua Jin
Journal:  Clin Cancer Res       Date:  2014-06-23       Impact factor: 12.531

2.  miR-320 regulates tumor angiogenesis driven by vascular endothelial cells in oral cancer by silencing neuropilin 1.

Authors:  Yi-Ying Wu; Yuh-Ling Chen; Yun-Chia Jao; I-Shan Hsieh; Kung-Chao Chang; Tse-Ming Hong
Journal:  Angiogenesis       Date:  2013-10-10       Impact factor: 9.596

3.  MicroRNA expression profiling of oral carcinoma identifies new markers of tumor progression.

Authors:  L Scapoli; A Palmieri; L Lo Muzio; F Pezzetti; C Rubini; A Girardi; F Farinella; M Mazzotta; F Carinci
Journal:  Int J Immunopathol Pharmacol       Date:  2010 Oct-Dec       Impact factor: 3.219

4.  Structural studies of neuropilin/antibody complexes provide insights into semaphorin and VEGF binding.

Authors:  Brent A Appleton; Ping Wu; Janice Maloney; JianPing Yin; Wei-Ching Liang; Scott Stawicki; Kyle Mortara; Krista K Bowman; J Michael Elliott; William Desmarais; J Fernando Bazan; Anil Bagri; Marc Tessier-Lavigne; Alexander W Koch; Yan Wu; Ryan J Watts; Christian Wiesmann
Journal:  EMBO J       Date:  2007-11-08       Impact factor: 11.598

5.  miR-200a inhibits tumor proliferation by targeting AP-2γ in neuroblastoma cells.

Authors:  Shun-Li Gao; Li-Zhong Wang; Hai-Ying Liu; Dan-Li Liu; Li-Ming Xie; Zhi-Wei Zhang
Journal:  Asian Pac J Cancer Prev       Date:  2014

6.  miR-338-3p suppresses neuroblastoma proliferation, invasion and migration through targeting PREX2a.

Authors:  Xin Chen; Min Pan; Lulu Han; Hongting Lu; Xiwei Hao; Qian Dong
Journal:  FEBS Lett       Date:  2013-10-15       Impact factor: 4.124

7.  MicroRNA-338-3p inhibits colorectal carcinoma cell invasion and migration by targeting smoothened.

Authors:  Qi Xue; Kai Sun; Hai-Jun Deng; Shang-Tong Lei; Jing-Qing Dong; Guo-Xin Li
Journal:  Jpn J Clin Oncol       Date:  2013-11-25       Impact factor: 3.019

8.  MicroRNA-338 inhibits growth, invasion and metastasis of gastric cancer by targeting NRP1 expression.

Authors:  Yang Peng; Yan-Min Liu; Lu-Chun Li; Lu-Lu Wang; Xiao-Ling Wu
Journal:  PLoS One       Date:  2014-04-15       Impact factor: 3.240

9.  miR-1 and miR-133b are differentially expressed in patients with recurrent prostate cancer.

Authors:  Omer Faruk Karatas; Esra Guzel; Ilknur Suer; Isin D Ekici; Turhan Caskurlu; Chad J Creighton; Michael Ittmann; Mustafa Ozen
Journal:  PLoS One       Date:  2014-06-26       Impact factor: 3.240

10.  MicroRNAs define distinct human neuroblastoma cell phenotypes and regulate their differentiation and tumorigenicity.

Authors:  Leleesha Samaraweera; Kathryn B Grandinetti; Ruojun Huang; Barbara A Spengler; Robert A Ross
Journal:  BMC Cancer       Date:  2014-05-02       Impact factor: 4.430

View more
  17 in total

1.  Neuropilin-1 upregulation elicits adaptive resistance to oncogene-targeted therapies.

Authors:  Sabrina Rizzolio; Gabriella Cagnoni; Chiara Battistini; Stefano Bonelli; Claudio Isella; Jo A Van Ginderachter; René Bernards; Federica Di Nicolantonio; Silvia Giordano; Luca Tamagnone
Journal:  J Clin Invest       Date:  2018-08-13       Impact factor: 14.808

2.  MiR-338-5p sensitizes glioblastoma cells to radiation through regulation of genes involved in DNA damage response.

Authors:  Andrej Besse; Jiri Sana; Radek Lakomy; Leos Kren; Pavel Fadrus; Martin Smrcka; Marketa Hermanova; Radim Jancalek; Stefan Reguli; Radim Lipina; Marek Svoboda; Pavel Slampa; Ondrej Slaby
Journal:  Tumour Biol       Date:  2015-12-21

3.  MECP2 promotes the growth of gastric cancer cells by suppressing miR-338-mediated antiproliferative effect.

Authors:  Dongdong Tong; Lingyu Zhao; Kang He; Hongfei Sun; Donghui Cai; Lei Ni; Ruifang Sun; Su'e Chang; Tusheng Song; Chen Huang
Journal:  Oncotarget       Date:  2016-06-07

4.  MiR-139-5p inhibits the tumorigenesis and progression of oral squamous carcinoma cells by targeting HOXA9.

Authors:  Kai Wang; Jun Jin; Tengxiao Ma; Hongfeng Zhai
Journal:  J Cell Mol Med       Date:  2017-08-05       Impact factor: 5.310

Review 5.  TRAIL, Wnt, Sonic Hedgehog, TGFβ, and miRNA Signalings Are Potential Targets for Oral Cancer Therapy.

Authors:  Ammad Ahmad Farooqi; Chih-Wen Shu; Hurng-Wern Huang; Hui-Ru Wang; Yung-Ting Chang; Sundas Fayyaz; Shyng-Shiou F Yuan; Jen-Yang Tang; Hsueh-Wei Chang
Journal:  Int J Mol Sci       Date:  2017-07-14       Impact factor: 5.923

6.  miR-195-5p Suppresses the Proliferation, Migration, and Invasion of Oral Squamous Cell Carcinoma by Targeting TRIM14.

Authors:  Tong Wang; Yipeng Ren; Ruixun Liu; Juntao Ma; Yueyi Shi; Lei Zhang; Rongfa Bu
Journal:  Biomed Res Int       Date:  2017-10-24       Impact factor: 3.411

7.  Effects of miR-338 on morphine tolerance by targeting CXCR4 in a rat model of bone cancer pain.

Authors:  Hong-Xia Mei; Min-Hong Zhou; Xing-Wang Zhang; Xi-Xi Huang; Yong-Le Wang; Pei-Fang Wang; Gong-Hao Zhan
Journal:  Biosci Rep       Date:  2017-03-15       Impact factor: 3.840

8.  Spatiotemporal microRNA profile in peripheral nerve regeneration: miR-138 targets vimentin and inhibits Schwann cell migration and proliferation.

Authors:  Travis B Sullivan; Litchfield C Robert; Patrick A Teebagy; Shannon E Morgan; Evan W Beatty; Bryan J Cicuto; Peter K Nowd; Kimberly M Rieger-Christ; David J Bryan
Journal:  Neural Regen Res       Date:  2018-07       Impact factor: 5.135

Review 9.  Neuropilins Controlling Cancer Therapy Responsiveness.

Authors:  Virginia Napolitano; Luca Tamagnone
Journal:  Int J Mol Sci       Date:  2019-04-25       Impact factor: 5.923

10.  Epigenetic silencing of miR-338 facilitates glioblastoma progression by de-repressing the pyruvate kinase M2-β-catenin axis.

Authors:  Bo Han; Xiangqi Meng; Hui Chen; Lingchao Chen; Xing Liu; Hongjun Wang; Daming Liu; Fei Gao; Lin Lin; Jianguang Ming; Bo Sun; Shi Yin; Ruijia Wang; Pengfei Wu; Jinquan Cai; Chuanlu Jiang
Journal:  Aging (Albany NY)       Date:  2017-08-02       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.